CG
BCTX

Cutler Group’s Briacell Therapeutics BCTX Stock Holding History

Cutler Group’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-47
Closed -$1K – 4386
2022
Q3 		$1K Buy
+47
New +$47.2K ﹤0.01% 4426
2022
Q2 		– Sell
-27
Closed -$1K – 4965
2022
Q1 		$1K Sell
27
-66
-71% -$78.1K ﹤0.01% 4889
2021
Q4 		$10K Buy
+93
New +$122K ﹤0.01% 3670

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Cutler Group's BCTX Position: Q4 2022 in Review

Cutler Group sold out of Briacell Therapeutics (BCTX) in Q4 2022, closing a stake of 9 shares — an estimated $7K sold.

Cutler Group first reported a position in BCTX in Q2 2022 and held it in 2 quarters. The position peaked at $7K in Q3 2022. 18 funds tracked by Wall St. Rank hold BCTX as of Q4 2022.

  • Cutler Group reported no remaining Briacell Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 9 Briacell Therapeutics shares in Q4 2022, an estimated $7K.
  • Cutler Group first reported a position in Briacell Therapeutics in Q2 2022 and held it in 2 quarters.
  • Cutler Group's Briacell Therapeutics position peaked at $7K in Q3 2022.
  • 18 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.